lafora disease/carbohydrate

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 35 rezilta yo

A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease (progressive myoclonus epilepsy of Lafora type) is an autosomal recessive neurodegenerative disorder resulting from defects in the EPM2A gene. EPM2A encodes a 331-amino acid protein containing a carboxyl-terminal phosphatase catalytic domain. We demonstrate that the EPM2A gene product

Laforin in autophagy: a possible link between carbohydrate and protein in Lafora disease?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The progressive myoclonus epilepsy of Lafora disease (LD) is a fatal form of neurodegenerative disorder associated with progressive intellectual decline and ataxia in addition to epilepsy. The disease can be caused by defects in the EPM2A gene encoding laforin phosphatase or the NHLRC1 gene encoding

The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora's disease (LD) is an autosomal recessive and fatal form of epilepsy with onset in late childhood or adolescence. One of the characteristic features of LD pathology is the presence of periodic acid-Schiff (PAS) positive Lafora inclusion bodies. Lafora bodies are present primarily in neurons,

The retina in Lafora disease: light and electron microscopy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora bodies are described in the retina of a 16 year old female who died five years after the onset of a typical familial progressive myoclonus epilepsy which was diagnosed as Lafora disease by brain biopsy and by autopsy findings. The patient was the offspring of consanguinous parents who had

Lafora disease in the cow?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease in man is an autosomal recessive defect which affects carbohydrate metabolism and results in a progressive, ultimately fatal neurological condition. It is characterized histologically by intraneuronal cytoplasmic polyglucosan inclusions (Lafora bodies). Similar inclusions have been

Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease (LD) is a fatal autosomal recessive form of progressive myoclonus epilepsy. Patients manifest myoclonus and tonic-clonic seizures, visual hallucinations, intellectual, and progressive neurologic deterioration beginning in adolescence. The two genes known to be involved in Lafora

Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease is a progressive myoclonus epilepsy with an early fatal issue. Two genes were identified thus far, the mutations of which cause the disease. The first one, EPM2A, encodes the consensus sequence of a protein tyrosine phosphatase. Its product, laforin, is the object of the present work.

Biophysical characterization of laforin-carbohydrate interaction.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Laforin is a human dual-specificity phosphatase (DSP) involved in glycogen metabolism regulation containing a carbohydrate-binding module (CBM). Mutations in the gene coding for laforin are responsible for the development of Lafora disease, a progressive fatal myoclonus epilepsy with early onset,

Exploring the structural insights on human laforin mutation K87A in Lafora disease--a molecular dynamics study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease (LD) is an autosomal recessive, progressive form of myoclonus epilepsy which affects worldwide. LD occurs mainly in countries like southern Europe, northern Africa, South India, and in the Middle East. LD occurs with its onset mainly in teenagers and leads to decline and death within

Pyruvate metabolism in Lafora disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease is an autosomal recessive and progressive degenerative disorder of the central nervous system (CNS). The pathogenic mechanism has been presumed to be an inborn error of carbohydrate metabolism, although this has never been proved. In a case of proven Lafora disease, pyruvate

Lafora disease: liver histopathology in presymptomatic children.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease is an inborn error of carbohydrate metabolism with storage of a polyglucosan in various tissues including brain and liver. Recently, distinctive histopathological changes in liver have been emphasized, and the diagnosis has been confirmed by the relatively simple procedure of

Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora Disease (LD) is a fatal neurodegenerative epileptic disorder that presents as a neurological deterioration with the accumulation of insoluble, intracellular, hyperphosphorylated carbohydrates called Lafora bodies (LBs). LD is caused by mutations in either the gene encoding laforin or malin.

Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Progressive Myoclonus Epilepsy (PME) of the Lafora type is an autosomal recessive disease, which presents in teenage years with myoclonia and generalized seizures leading to death within a decade of onset. It is characterized by pathognomonic inclusions, Lafora bodies (LB), in neurons and other cell

The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lafora disease (LD) is a progressive myoclonic epilepsy resulting in severe neurodegeneration followed by death. A hallmark of LD is the accumulation of insoluble polyglucosans called Lafora bodies (LBs). LD is caused by mutations in the gene encoding the phosphatase laforin, which reportedly exists

Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Laforin is the only phosphatase in the animal kingdom that contains a carbohydrate-binding module. Mutations in the gene encoding laforin result in Lafora disease, a fatal autosomal recessive neurodegenerative disorder, which is diagnosed by the presence of intracellular deposits of insoluble

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye